Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus.
Fiche publication
Date publication
mai 2021
Journal
Autoimmunity reviews
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
D'Amico F, Solitano V, Aletaha D, Hart A, Magro F, Selmi C, Ng SC, Al Awadhi S, Choy E, Schulze-Koops H, Bossuyt P, Olivera PA, Kotze PG, Ghosh S, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
Several efforts have been made to improve the available therapeutic armamentarium of patients with immune-mediated inflammatory disorders (IMIDs) leading to the development of biobetters. To date, there is no commonly accepted definition of biobetters. Sixteen physicians with expertise in the field of IMIDs from eleven countries attended a virtual international consensus meeting to provide for the first time a definition of biobetter and to identify unmet needs on this topic. Improvements in clinical outcomes and drug pharmacology were considered crucial for the definition of biobetters, while safety profile and patient acceptability were not. In addition, an appropriate balance between clinical outcomes and costs and a shared decision between physicians and patients should guide the decision to use a biobetter. Clinical studies are required to validate the biobetter definition and to investigate their role in the management of patients with IMIDs.
Mots clés
Biobetters, Consensus, Definition, Immune-mediated inflammatory disorders
Référence
Autoimmun Rev. 2021 May 8;:102849